US’ at present rejected the emergency use authorisation for Covaxin. (Representational)
The centre at present stated that it respects the US’ determination to reject the emergency use authorisation for Covaxin, nonetheless, the identical won’t have an effect on India’s vaccine plan.
“Every country’s regulatory system might have some things in common with others and some things different. We respect it. The scientific framework is the same but its nuancing is as per the context. All of these are scientific considerations and keeping those in mind, the nuancing might be different, especially in those countries where science is strong. Our manufacturing is strong. They have decided this. We respect it,” Member-Health, Niti Aayog Dr VK Paul stated.
Dr VK Paul additionally expressed hope that the vaccine maker will adjust to what the FDA has wished.
“We expect that our manufacturers will be able to comply with it. It has no impact on our own program. Our regulator has approved it,” he added.
Dr Paul additionally talked about that the publication of Covaxin’s part 3 trial can be completed someday in 7-8 days.
“A vaccine manufactured in India may not be equally effective in Argentina,” Dr Paul stated, citing the instance of the Rota Virus for Children.
“The nutrition level, the gut flora of the population make a difference in the effect of the Rota Virus. This may lead to some differences especially in countries where science is strong, and our manufacturing is strong,” Dr Paul stated.
